Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

540 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Same-session endoscopic diagnosis and symptom palliation in pancreato-biliary malignancies: Clinical impact of rapid on-site evaluation (ROSE).
Vanella G, Dell'Anna G, Cosenza A, Pedica F, Petrone MC, Mariani A, Archibugi L, Rossi G, Tacelli M, Zaccari P, Leone R, Tamburrino D, Belfiori G, Falconi M, Aldrighetti L, Reni M, Casadei Gardini A, Doglioni C, Capurso G, Arcidiacono PG. Vanella G, et al. Among authors: aldrighetti l. Endosc Int Open. 2024 Feb 28;12(2):E297-E306. doi: 10.1055/a-2251-3551. eCollection 2024 Feb. Endosc Int Open. 2024. PMID: 38420151 Free PMC article.
High sensitivity of ROSE-supported ERCP-guided brushing for biliary strictures.
Archibugi L, Mariani A, Ciambriello B, Petrone MC, Rossi G, Testoni SGG, Carlucci M, Aldrighetti L, Falconi M, Balzano G, Doglioni C, Capurso G, Arcidiacono PG. Archibugi L, et al. Among authors: aldrighetti l. Endosc Int Open. 2021 Mar;9(3):E363-E370. doi: 10.1055/a-1322-2638. Epub 2021 Feb 19. Endosc Int Open. 2021. PMID: 33655035 Free PMC article.
Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis.
Rimini M, Rimassa L, Ueshima K, Burgio V, Shigeo S, Tada T, Suda G, Yoo C, Cheon J, Pinato DJ, Lonardi S, Scartozzi M, Iavarone M, Di Costanzo GG, Marra F, Soldà C, Tamburini E, Piscaglia F, Masi G, Cabibbo G, Foschi FG, Silletta M, Pressiani T, Nishida N, Iwamoto H, Sakamoto N, Ryoo BY, Chon HJ, Claudia F, Niizeki T, Sho T, Kang B, D'Alessio A, Kumada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimur T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tanaka T, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Naganuma A, Koizumi Y, Nakamura S, Joko K, Iijima H, Hiasa Y, Pedica F, De Cobelli F, Ratti F, Aldrighetti L, Kudo M, Cascinu S, Casadei-Gardini A. Rimini M, et al. Among authors: aldrighetti l. ESMO Open. 2022 Dec;7(6):100591. doi: 10.1016/j.esmoop.2022.100591. Epub 2022 Oct 6. ESMO Open. 2022. PMID: 36208496 Free PMC article.
Molecular profile and its clinical impact of IDH1 mutated versus IDH1 wild type intrahepatic cholangiocarcinoma.
Rimini M, Fabregat-Franco C, Burgio V, Lonardi S, Niger M, Scartozzi M, Rapposelli IG, Aprile G, Ratti F, Pedica F, Verdaguer H, Rizzato M, Nichetti F, Lai E, Cappetta A, Macarulla T, Fassan M, De Braud F, Pretta A, Simionato F, De Cobelli F, Aldrighetti L, Fornaro L, Cascinu S, Casadei-Gardini A. Rimini M, et al. Among authors: aldrighetti l. Sci Rep. 2022 Nov 5;12(1):18775. doi: 10.1038/s41598-022-22543-z. Sci Rep. 2022. PMID: 36335135 Free PMC article.
Clinical Outcomes After Progression on First-Line Therapies in IDH1 Mutated Versus Wild-Type Intrahepatic Cholangiocarcinoma Patients.
Rimini M, Fabregat-Franco C, Persano M, Burgio V, Bergamo F, Niger M, Scartozzi M, Rapposelli IG, Aprile G, Ratti F, Pedica F, Verdaguer H, Rizzato M, Nichetti F, Lai E, Cappetta A, Macarulla T, Fassan M, De Braud F, Pretta A, Simionato F, De Cobelli F, Aldrighetti L, Fornaro L, Cascinu S, Casadei-Gardini A. Rimini M, et al. Among authors: aldrighetti l. Target Oncol. 2023 Jan;18(1):139-145. doi: 10.1007/s11523-022-00933-7. Epub 2023 Jan 23. Target Oncol. 2023. PMID: 36689074
EUS-guided gastroenterostomy for management of malignant gastric outlet obstruction: a prospective cohort study with matched comparison with enteral stenting.
Vanella G, Dell'Anna G, Capurso G, Maisonneuve P, Bronswijk M, Crippa S, Tamburrino D, Macchini M, Orsi G, Casadei-Gardini A, Aldrighetti L, Reni M, Falconi M, van der Merwe S, Arcidiacono PG. Vanella G, et al. Among authors: aldrighetti l. Gastrointest Endosc. 2023 Sep;98(3):337-347.e5. doi: 10.1016/j.gie.2023.04.2072. Epub 2023 Apr 23. Gastrointest Endosc. 2023. PMID: 37094692
Revealing and harnessing CD39 for the treatment of colorectal cancer and liver metastases by engineered T cells.
Potenza A, Balestrieri C, Spiga M, Albarello L, Pedica F, Manfredi F, Cianciotti BC, De Lalla C, Botrugno OA, Faccani C, Stasi L, Tassi E, Bonfiglio S, Scotti GM, Redegalli M, Biancolini D, Camisa B, Tiziano E, Sirini C, Casucci M, Iozzi C, Abbati D, Simeoni F, Lazarevic D, Elmore U, Fiorentini G, Di Lullo G, Casorati G, Doglioni C, Tonon G, Dellabona P, Rosati R, Aldrighetti L, Ruggiero E, Bonini C. Potenza A, et al. Among authors: aldrighetti l. Gut. 2023 Oct;72(10):1887-1903. doi: 10.1136/gutjnl-2022-328042. Epub 2023 Jun 30. Gut. 2023. PMID: 37399271
540 results